Warfarin Cohort (N = 125,257)		Apixaban Cohort (N = 38,906)		Dabigatran Cohort (N = 20,979)		Rivaroxaban Cohort (N = 79,337)
	n/mean	%/SD	n/mean	%/SD	n/mean	%/SD	n/mean	%/SD
Age (years)	78.56	7.37	78.30	7.38	77.07	7.00	77.53	7.16
65-74	41,678	33.27%	13,648	35.08%	8,585	40.92%	30,663	38.65%
75-84	54,186	43.26%	16,470	42.33%	8,830	42.09%	33,772	42.57%
≥ 85	29,393	23.47%	8,788	22.59%	3,564	16.99%	14,902	18.78%
Gender
Male	60,638	48.41%	18,438	47.39%	10,647	50.75%	38,518	48.55%
Female	64,619	51.59%	20,468	52.61%	10,332	49.25%	40,819	51.45%
Geographic region
Northeast	24,944	19.91%	7,110	18.27%	4,239	20.21%	14,298	18.02%
North Central	38,533	30.76%	8,115	20.86%	4,882	23.27%	18,387	23.18%
South	40,386	32.24%	17,383	44.68%	7,987	38.07%	32,912	41.48%
West	21,241	16.96%	6,272	16.12%	3,837	18.29%	13,592	17.13%
Other	153	0.12%	26	0.07%	34	0.16%	148	0.19%
Baseline comorbidity
Charlson Comorbidity Index	3.10	2.76	2.70	2.55	2.46	2.40	2.58	2.49
CHADS2 scorea	2.84	1.45	2.70	1.43	2.57	1.41	2.60	1.43
CHA2DS2-VASc scoreb	4.71	1.75	4.55	1.73	4.35	1.71	4.43	1.72
HAS-BLED scorec	3.29	1.30	3.23	1.24	3.07	1.21	3.17	1.23
Baseline prior bleed	31,052	24.79%	7,921	20.36%	3,878	18.49%	16,932	21.34%
Baseline prior stroke	19,297	15.41%	4,746	12.20%	2,377	11.33%	9,021	11.37%
Congestive heart failure	43,374	34.63%	11,295	29.03%	5,753	27.42%	21,517	27.12%
Diabetes	50,006	39.92%	13,884	35.69%	7,683	36.62%	28,152	35.48%
Hypertension	108,611	86.71%	34,276	88.10%	18,152	86.52%	69,011	86.98%
Renal disease	36,657	29.27%	9,175	23.58%	3,902	18.60%	16,045	20.22%
Myocardial infarction	18,638	14.88%	4,906	12.61%	2,253	10.74%	9,400	11.85%
Dyspepsia or stomach discomfort	26,535	21.18%	8,215	21.11%	4,049	19.30%	16,489	20.78%
Peripheral vascular disease	69,381	55.39%	21,502	55.27%	10,762	51.30%	41,938	52.86%
Transient ischemic attack	9,789	7.82%	3,044	7.82%	1,527	7.28%	5,829	7.35%
Coronary artery disease	59,249	47.30%	18,698	48.06%	9,276	44.22%	35,963	45.33%
Follow-up time (days)	179.31	173.59	144.66	133.32	185.02	183.82	178.76	174.67
Median	111		97		106		113
All-cause hospitalization incidence rate (per 100 person-years)	60.72		47.25		45.27		53.31
Stroke/SE incidence rate (per 100 person-years)	1.98		0.97		1.40		1.25
Ischemic stroke	1.43		0.79		1.21		0.87
Hemorrhage stroke	0.42		0.14		0.13		0.29
SE	0.13		0.04		0.06		0.08
Major bleeding incidence rate (per 100 person-years)	6.56		3.64		4.18		6.30
Gastrointestinal bleeding	3.12		1.83		2.58		3.53
Intracranial hemorrhage	0.99		0.36		0.44		0.61
Other bleeding	2.80		1.67		1.48		2.65
Follow-up all-cause health care costs ($ PPPM)
All-cause ER/outpatient medical costs	1,826	8,058	1,145	5,333	1,301	6,081	1,645	7,310
All-cause hospitalization medical costs	1,024	2,571	901	1,893	874	1,893	966	2,920
Pharmacy costs	375	885	780	1,690	659	1,046	701	1,097
All-cause health care costs	3,987	9,904	3,179	6,733	3,210	7,310	3,941	9,030

^aCHADS₂: congestive heart failure, hypertension, aged ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or venous thromboembolism.

^bCHA₂DS₂-VASc: congestive heart failure, hypertension, aged ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65-74 years, sex category.

^cHAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol.

ER = emergency room; PPPM = per patient per month; PSM = propensity score matching; SD = standard deviation; SE = systemic embolism.